Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032)
PHASE1CompletedINTERVENTIONAL
Enrollment
44
Participants
Timeline
Start Date
August 4, 2016
Primary Completion Date
September 19, 2017
Study Completion Date
December 31, 2021
Conditions
Non-Small-Cell Lung Cancer
Interventions
BIOLOGICAL
Pembrolizumab
IV infusion
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT02835690 - Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032) | Biotech Hunter | Biotech Hunter